Author:
Al-Batran S.-E.,Van Cutsem E.,Oh S.C.,Bodoky G.,Shimada Y.,Hironaka S.,Sugimoto N.,Lipatov O.N.,Kim T.-Y.,Cunningham D.,Rougier P.,Muro K.,Liepa A.M.,Chandrawansa K.,Emig M.,Ohtsu A.,Wilke H.
Reference19 articles.
1. J Ferlay, I Soerjomataram, M Ervik et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr, accessed on 16 May 2015.
2. Management of advanced gastric cancer;Price;Expert Rev Gastroenterol Hepatol,2012
3. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO);Thuss-Patience;Eur J Cancer,2011
4. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone;Kang;J Clin Oncol,2012
5. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial;Ford;Lancet Oncol,2014